Hereditary Angioedema Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Hereditary Angioedema Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Aug 2017 Transparency Market Research Pharmaceutical153 Pages Price :
$ 5795

Global Hereditary Angioedema Market: Scope and Methodology

This report on the global hereditary angioedema market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment and sub-segment for the period from 2017 to 2025, considering the macro and micro environmental factors. Growth rates for each segment within the global hereditary angioedema market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global hereditary angioedema market.

Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year. Market size estimations involved in-depth study of product features of different types of drug class and various pipeline products. Additionally, market related factors such as rise in preference for self-administrable drugs, expiry of market exclusivity of certain drugs, projected launch of the drugs etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Hereditary Angioedema Market: Segmentation

Hereditary Angioedema is a rare genetic disease that is caused by lack or abnormal functioning of the protein C1 inhibitor protein. Lack of functional C1 inhibitor protein leads to high volume of bradykinin, which triggers of blood vessels causing inflammation of body organs. HAE symptoms are often misdiagnosed for common allergies or abdominal pain. Many patients are hospitalized due to HAE attacks. HAE attack in upper airway have proven to be fatal if untreated on its emergence.

Based on drug class, the global hereditary angioedema market has been segmented into C1 esterase inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor others. The C1 esterase inhibitor is further segmented into drugs namely Cinryze, Berinert and Ruconest. The segment is anticipated to hold a significant share of the global market. The others segment is further sun segmented into conventional and pipeline products. The segment is projected to dominate the market during the forecast period due to launch of novel products.

Based on route of administration, the global hereditary angioedema market is segmented into intravenous, subcutaneous injections and oral. The subcutaneous injections is anticipated to dominate the market during the forecast period due to availability of approved drugs for acute HAE attack are administered subcutaneously, development of variants of Cinryze and Berinert that can be administered subcutaneously etc.

Based on the distribution channel, the global hereditary angioedema market is segmented into hospital pharmacies, retail pharmacies and others.    Ever increasing number of retail pharmacies is attributed for the significant share of the segment in the global market.

Hereditary Angioedema Market: Geographical and Competitive Dynamics

Geographically, the global hereditary angioedema market has been segmented into six regions: North America, Europe, Asia Pacific and Rest of the World. In addition, the regions have been further segmented by major countries from each region.

The report also profiles major players in the hereditary angioedema market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Shire plc, CSL Limited, Pharming Group NV, Ionis Pharmaceuticals, Inc. and iBio, Inc.

The global hereditary angioedema market has been segmented as below:

Global Hereditary Angioedema Market, by Drug Class

  • C1 Esterase Inhibitor
  • Cinryze
  • Berinert
  • Ruconest
  • Selective Bradykinin B2 Receptor Antagonist
  • Firazyr
  • Kallikrein Inhibitor
  • Kalbitor
  • Others
  • Conventional Drugs (attenuated androgens, antifibrinolytic agents
  • Pipeline Products (DX-2930, BCX-7353)

Global Hereditary Angioedema Market, by Route of Administration

  • Intravenous
  • Subcutaneous Injection
  • Oral

Global Hereditary angioedema Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Global Hereditary Angioedema Market, by Geography

  • North America
  • Europe
  • Rest of the World

Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hereditary Angioedema Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Market Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.3.4. Trends
4.4. Hereditary Angioedema Market Analysis and Forecast, 2017 – 2025
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Market Outlook
4.6. Porter’s five forces analysis
4.7. Value Chain Analysis
4.8. Pipeline Analysis
4.9. Orphan Drug Exclusivity Details
4.10. Disease Overview

5. Global Hereditary Angioedema Market Analysis and Forecasts, By Drug Class
5.1. Introduction & Definition
5.2. Key Findings
5.3. Key Trends
5.4. Market Size (US$ Mn) Forecast By Drug Class
5.4.1. C1 esterase inhibitor
5.4.1.1. Cinryze
5.4.1.2. Berinert
5.4.1.3. Ruconest
5.4.2. Selective bradykinin B2 receptor antagonist
5.4.2.1. Firazyr
5.4.3. Kallikrein inhibitor
5.4.3.1. Kalbitor
5.4.4. Others
5.4.4.1. Conventional Drugs
5.4.4.2. Pipeline Drugs
5.5. Comparison Matrix
5.6. Market Attractiveness By Drug Class

6. Global Hereditary Angioedema Market Analysis and Forecasts, By Route of Administration
6.1. Introduction & Definition
6.2. Key Findings
6.3. Market Size (US$ Mn) Forecast By Route of Administration
6.3.1. Intravenous
6.3.2. Subcutaneous injection
6.3.3. Oral
6.4. Comparison Matrix
6.5. Market Attractiveness By Route of Administration

7. Global Hereditary Angioedema Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings
7.3. Key Trends
7.4. Market Size (US$ Mn) Forecast By Distribution Channel
7.4.1. Hospital pharmacies
7.4.2. Retail pharmacies
7.4.3. Others
7.5. Comparison Matrix
7.6. Market Attractiveness By Distribution Channel

8. Global Hereditary Angioedema Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Key Trends
8.3. Market Size (US$ Mn) Forecast By Region
8.3.1. North America
8.3.2. Europe
8.3.3. Rest of the World
8.4. Market Attractiveness By Region

9. North America Hereditary Angioedema Market Analysis and Forecast
9.1. Key Findings
9.2. Policies and Regulations
9.3. Market Overview
9.4. Market Size (US$ Mn) Forecast By Drug Class
9.4.1. C1 esterase inhibitor
9.4.1.1. Cinryze
9.4.1.2. Berinert
9.4.1.3. Ruconest
9.4.2. Selective bradykinin B2 receptor antagonist
9.4.2.1. Firazyr
9.4.3. Kallikrein inhibitor
9.4.3.1. Kalbitor
9.4.4. Others
9.4.4.1. Conventional Drugs
9.4.4.2. Pipeline Drugs
9.5. Market Size (US$ Mn) Forecast By Route of Administration
9.5.1. Intravenous
9.5.2. Subcutaneous injection
9.5.3. Oral
9.6. Market Size (US$ Mn) Forecast By Distribution Channel
9.6.1. Hospital pharmacies
9.6.2. Retail pharmacies
9.6.3. Others
9.7. Market Size by Value (US$ Mn) Forecast, By Country
9.7.1. U.S.
9.7.2. Canada
9.8. Market Attractiveness Analysis
9.8.1. By Drug Class
9.8.2. By Route of Administration
9.8.3. By Distribution Channel
9.8.4. By Country

10. Europe Hereditary Angioedema Market Analysis and Forecast
10.1. Key Findings
10.2. Policies and Regulations
10.3. Market Overview
10.4. Market Size (US$ Mn) Forecast By Drug Class
10.4.1. C1 esterase inhibitor
10.4.1.1. Cinryze
10.4.1.2. Berinert
10.4.1.3. Ruconest
10.4.2. Selective bradykinin B2 receptor antagonist
10.4.2.1. Firazyr
10.4.3. Others
10.4.3.1. Conventional Drugs
10.4.3.2. Pipeline Drugs
10.5. Market Size (US$ Mn) Forecast By Route of Administration
10.5.1. Intravenous
10.5.2. Subcutaneous injection
10.5.3. Oral
10.6. Market Size (US$ Mn) Forecast By Distribution Channel
10.6.1. Hospital pharmacies
10.6.2. Retail pharmacies
10.6.3. Others
10.7. Market Size by Value (US$ Mn) Forecast, By Country
10.7.1. Germany
10.7.2. U.K.
10.7.3. France
10.7.4. Spain
10.7.5. Italy
10.7.6. Rest of Europe
10.8. Market Attractiveness Analysis
10.8.1. By Drug Class
10.8.2. By Route of Administration
10.8.3. By Distribution Channel
10.8.4. By Country / Sub-region

11. Rest of The World Hereditary Angioedema Market Analysis and Forecast
11.1. Key Findings
11.2. Policies and Regulations
11.3. Market Overview
11.4. Market Size (US$ Mn) Forecast By Drug Class
11.4.1. C1 esterase inhibitor
11.4.1.1. Cinryze
11.4.1.2. Berinert
11.4.1.3. Ruconest
11.4.2. Selective bradykinin B2 receptor antagonist
11.4.2.1. Firazyr
11.4.3. Kallikrein inhibitor
11.4.3.1. Kalbitor
11.4.4. Others
11.4.4.1. Conventional Drugs
11.4.4.2. Pipeline Drugs
11.5. Market Size (US$ Mn) Forecast By Route of Administration
11.5.1. Intravenous
11.5.2. Subcutaneous injection
11.5.3. Oral
11.6. Market Size (US$ Mn) Forecast By Distribution Channel
11.6.1. Hospital pharmacies
11.6.2. Retail pharmacies
11.6.3. Others
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Route of Administration
11.7.3. By Distribution Channel

12. Competition Landscape
12.1. Market Share Analysis
12.2. Market Player – Competition Matrix (By Tier and Size of companies)
12.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
12.3.1. Shire plc
12.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
12.3.1.2. Product Portfolio
12.3.1.3. SWOT Analysis
12.3.1.4. Financial Overview
12.3.1.5. Strategic Overview
12.3.2. CSL Limited
12.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
12.3.2.2. Product Portfolio
12.3.2.3. SWOT Analysis
12.3.2.4. Financial Overview
12.3.2.5. Strategic Overview
12.3.3. Pharming Group NV
12.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
12.3.3.2. Product Portfolio
12.3.3.3. SWOT Analysis
12.3.3.4. Financial Overview
12.3.3.5. Strategic Overview
12.3.4. Ionis Pharmaceuticals, Inc.
12.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
12.3.4.2. Product Portfolio
12.3.4.3. SWOT Analysis
12.3.4.4. Financial Overview
12.3.4.5. Strategic Overview
12.3.5. iBio Inc.
12.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
12.3.5.2. Product Portfolio
12.3.5.3. SWOT Analysis
12.3.5.4. Financial Overview
12.3.5.5. Strategic Overview
12.2.6. BioCryst Pharmaceuticals, Inc.
12.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
12.3.6.2. Product Portfolio
12.3.6.3. SWOT Analysis
12.3.6.4. Financial Overview
12.3.6.5. Strategic Overview

List of Table

Table 01: Pipeline Analysis, by Phase III
Table 02: Pipeline Analysis, By Phase II and Phase I
Table 03: Pipeline Analysis, By Preclinical Trial (1/2)
Table 04: Pipeline Analysis, By Preclinical Trial (2/2)
Table 05: Orphan Drug Exclusivity (1/3)
Table 06: Orphan Drug Exclusivity (2/3)
Table 07: Orphan Drug Exclusivity (3/3)
Table 08: Disease Overview by Type of HAE
Table 09: Reported and Estimated Cases of HAE, By Country
Table 10: Global Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 11: Global Hereditary Angioedema Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2015–2025
Table 12: Global Hereditary Angioedema Market Value (US$ Mn) Forecast, by Others, 2015–2025
Table 13: Global Hereditary Angioedema Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 14: Global Hereditary Angioedema Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 15: Global Hereditary Angioedema Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 16: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 17: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2015–2025
Table 18: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class - Others, 2015–2025
Table 19: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 20: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 21: North America Hereditary Angioedema Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 22: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 23: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by C1 esterase inhibitor, 2015–2025
Table 24: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by Others, 2015–2025
Table 25: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 26: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 27: Europe Hereditary Angioedema Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 28: Rest of the World Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 29: Rest of the World Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class - C1 Esterase Inhibitor, 2015–2025
Table 30: Rest of the World Hereditary Angioedema Market Value (US$ Mn) Forecast, by Drug Class - Others, 2015–2025
Table 31: Rest of the World Hereditary Angioedema Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 32: Rest of the World Hereditary Angioedema Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025

List of Chart

Figure 01: Global Hereditary Angioedema, by Drug Class, Market Size (US$ Mn), 2016 (A)
Figure 02: Global Hereditary Angioedema Market Revenue (%), by Route of Administration, 2016 (A)
Figure 03: Global Hereditary Angioedema Market Revenue (%), by Region, 2016 (A)
Figure 04: Opportunity Map, By Drug Class 2016
Figure 05: Opportunity Map, By Route of Administration and Distribution Channel 2016
Figure 06: Global Hereditary Angioedema Market - Key Industry Developments
Figure 07: Global Hereditary Angioedema Market – Key Drivers and Restraints
Figure 08: Global Hereditary Angioedema Market - Opportunity Analysis
Figure 09: Global Hereditary Angioedema Market Size (US$ Mn) Forecast, 2015–2025
Figure 10: Porter’s Five Forces Analysis
Figure 11: Global Hereditary Angioedema Market - Value Chain Analysis
Figure 12: Market Value Share, by Drug Class (2016)
Figure 13: Market Value Share, by Route of Administration (2016)
Figure 14: Market Value Share, by Distribution Channel (2016)
Figure 15: Global Hereditary Angioedema Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 16: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by C1 Esterase Inhibitor, 2015–2025
Figure 17: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Selective Bradykinin B2 Receptor Antagonist, 2015–2025
Figure 18: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Kallikrein Inhibitor, 2015–2025
Figure 19: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others,       2015–2025
Figure 20: Global Hereditary Angioedema Market Attractiveness Analysis, by Drug Class
Figure 21: Global Hereditary Angioedema Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 22: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Intravenous, 2015–2025
Figure 23: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Subcutaneous Injection, 2015–2025
Figure 24: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2015–2025
Figure 25: Global Hereditary Angioedema Market Attractiveness Analysis, by Route of Administration
Figure 26: Global Hereditary Angioedema Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 27: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015–2025
Figure 28: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2015–2025
Figure 29: Global Hereditary Angioedema Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
Figure 30: Global Hereditary Angioedema Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 31: Global Hereditary Angioedema Market Value Share Analysis, by Region, 2016 and 2025
Figure 32: Global Hereditary Angioedema Market Attractiveness Analysis, by Region
Figure 33: North America Hereditary Angioedema Market Size (US$ Mn) Forecast, 2017–2025
Figure 34: North America Hereditary Angioedema Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 35: North America Hereditary Angioedema Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 36: North America Hereditary Angioedema Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 37: North America Hereditary Angioedema Market Value Share Analysis, by Country, 2016 and 2025
Figure 38: North America Hereditary Angioedema Market Attractiveness Analysis, by Drug Class
Figure 39: North America Hereditary Angioedema Market Attractiveness Analysis, by Route of Administration
Figure 40: North America Hereditary Angioedema Market Attractiveness Analysis, by Distribution Channel
Figure 41: North America Market Attractiveness Analysis, by Country
Figure 42: Europe Hereditary Angioedema Market Size (US$ Mn) Forecast, 2017–2025
Figure 43: Europe Hereditary Angioedema Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 44: Europe Hereditary Angioedema Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 45: Europe Hereditary Angioedema Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 46: Europe Hereditary Angioedema Market Value Share Analysis, by Country, 2016 and 2025
Figure 47: Europe Hereditary Angioedema Market Attractiveness Analysis, by Drug Class
Figure 48: Europe Hereditary Angioedema Market Attractiveness Analysis, by Route of Administration
Figure 49: Europe Hereditary Angioedema Market Attractiveness Analysis, by Distribution Channel
Figure 50: Europe Market Attractiveness Analysis, by Country
Figure 51: Rest of the World Hereditary Angioedema Market Size (US$ Mn) Forecast, 2015–2025
Figure 52: Rest of the World Hereditary Angioedema Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 53: Rest of the World Hereditary Angioedema Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 54: Rest of the World Hereditary Angioedema Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 55: Rest of the World Hereditary Angioedema Market Attractiveness Analysis, by Drug Class
Figure 56: Rest of the World Hereditary Angioedema Market Attractiveness Analysis, by Route of Administration
Figure 57: Rest of the World Hereditary Angioedema Market Attractiveness Analysis, by Distribution Channel
Figure 58: Global Hereditary Angioedema Market Share Analysis, by Company (2016)
Figure 59: Shire Plc. Breakdown of Net Sales, by Segment, 2016
Figure 60: Shire Plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 61: CSL Limited Breakdown of Net Sales, by Region, 2015
Figure 62: CSL Limited Revenue (US$ Bn) and Y-o-Y Growth (%), 2012–2015
Figure 63: Pharming Group NV Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2016
Figure 64: Ionis Pharmaceuticals, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 65: iBio, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2016
Figure 66: BioCryst Pharmaceuticals, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 5795
$ 8795

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top